

**2016 (118)**

Abou-Ouf H, Zhao LN, Bismar TA. ERG expression in prostate cancer: biological relevance and clinical implication. *Journal of Clinical Research and Clinical Oncology*. 2016 Aug; 142 (8) 1781-1793

Al Nakouzi N, Wang CK, Beraldi E, Jager W, Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chauchereau A, Lorient Y, Gleave M. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. *EMBO Molecular Medicine*. 2016 July; 8 (7) 761-778

Almami A, Hegazy SA, Nabbi A, Alshalalfa M, Salman A, Abou-Ouf H, Riabowol K, Bismar TA. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients. *Tumor Biology*. 2016 July; 37 (7) 9731-9738

Bailey SD, Desai K, Kron KJ, Mazrooei P, Sinnott-Armstrong NA, Treloar AE, Dowar M, Thu KL, Cescon DW, Silvester J, Yang SYC, Wu X, Pezo RC, Haibe-Kains B, Mak TW, Bedard PL, Pugh TJ, Sallari RC, Lupien M. Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. *Nature Genetics*. 2016 Oct; 48 (10) 1260-1266

Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhaji R, Bijian K, Alaoui-Jamali MA, Bismar TA. MicroRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. *Molecular Biology Reports*. 2016 Apr; 43 (4) 229-240

Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Tetu B, Fradet Y, Lacombe L, Guillemette C, Levesque E. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. *European Urology*. 2016 Apr; 69 (4) 601-609

Bhindi B, Xie WY, Kulkarni GS, Hamilton RJ, Nesbitt M, Finelli A, Zlotta AR, Evans A, van der Kwast TH, Alibhai SMH, Trachtenberg J, Fleshner NE. Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. *Urology*. 2016 July; 93 77-84

Biggs CN, Siddiqui KM, Al-Zahrani AA, Pardhan S, Brett SI, Guo QQ, Yang J, Wolf P, Power NE, Durfee PN, MacMillan CD, Townson JL, Brinker JC, Fleshner NE, Izawa JI, Chambers AF, Chin JL, Leong HS. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry. *Europe PMC*. 2016 Feb; 7 (8) 8839-8849

Boutros PC, Fraser M, van der Kwast T, Bristow RG. Clonality of localized and metastatic prostate cancer. *Current Opinion in Urology*. 2016 May; 26 (3) 219-224

Box A, Alshalalfa M, Hegazy SA, Donnelly B, Bismar TA. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer. *Tumor Biology*. 2016 Sep; 37 (9) 12287-12299

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang WZ, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Maelandsmo GM, Svindland A, Barbier O, Tasken KA. Low beta(2)-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. *Oncotarget*. 2016 Jan; 7 (2) 1878-1894

Bujold KE, Hsu JCC, Sleiman HF. Optimized DNA "Nanosuitcases" for Encapsulation and Conditional Release of siRNA. *Journal of the American Chemical Society*. 2016 Oct; 138 (42) 14030-14038

Cetinbas NM, Sudderth J, Harris RC, Cebeci A, Negri GL, Yilmaz OH, DeBerardinis RJ, Sorensen PH. Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine. *Scientific Reports*. 2016 Sep; 6 32606

Charron CL, Hickey JL, Nsiama TK, Cruickshank DR, Turnbull WL, Luyt LG. Molecular imaging probes derived from natural peptides. *Natural Product Reports*. 2016 33 (6) 761-800

Chou LYT, Song FY, Chan WCW. Engineering the Structure and Properties of DNA-Nanoparticle Superstructures Using Polyvalent Counterions. *Journal of the American Chemical Society*. 2016 Apr; 138 (13) 4565-4572

Chowdhury S, Yung E, Pintilie M, Muaddi H, Chaib S, Yeung M, Fucciello M, Sykes J, Pitcher B, Hagenkort A, Mckee T, Vellanki R, Chen E, Bristow RG, Wouters BG, Koritzinsky M. MATE2 Expression Is Associated with Cancer Cell Response to Metformin. *PLoS One*. 2016 Dec; 11 e0165214

Chu J, Cargnello M, Topisirovic I, Pelletier J. Translation initiation factors: reprogramming protein synthesis in cancer. *Trends in Cell Biology*. 2016 Dec; 26 (12) 918-933

Chua MLK, Bristow RG. Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. *Clinical Cancer Research*. 2016 July; 22 (13) 3124-3126

Clausen TM, Pereira MA, Al Nakouzi N, Oo HZ, Agerbaek MO, Lee S, Orum-Madsen MS, Kristensen AR, El-Naggar A, Grandgenett PM, Grem JL, Hollingsworth MA, Holst PJ, Theander T, Sorensen PH, Daugaard M, Salanti A. Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility. *Molecular Cancer Research*. 2016 Dec; 14 (12) 1288-1299

Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZL, Parolia A, Wu R, Xue H, Wang YW, Ding JR, Thu KL, Lam WL, Shah SP, Collins CC, Wang YZ, Helgason CD. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. *Clinical Epigenetics*. 2016 Feb; 8 16

Cool DW, Romagnoli C, Izawa JI, Chin J, Gardi L, Tessier D, Mercado A, Mandel J, Ward AD, Fenster A. Comparison of prostate MRI-3D transrectal ultrasound fusion biopsy for first-time and repeat biopsy patients with previous atypical small acinar proliferation. *Canadian Urological Association Journal*. 2016 Oct; 10 (43017) 342-348

Cote MF, Turcotte A, Doillon C, Gobeil S. Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation. *Journal of Visualized Experiments*. 2016 Aug; 114 e54322

Crea F, Venalainen E, Ci XP, Cheng HW, Pikor L, Parolia A, Xue H, Saidy NRN, Lin D, Lam W, Collins C, Wang YZ. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. *Epigenomics*. 2016 May; 8 (5) 721-731

Cunningham CE, Li SS, Vizeacoumar FS, Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Abuhussein O, Paul JM, McDonald M, Templeton SD, Shukla H, El Zawily AM, Boyd F, Alli N, Mousseau DD, Geyer R, Bonham K, Anderson DH, Yan J, Yu-Lee LY, Weaver BA, Uppalapati M, Ruppin E, Sablina A, Freywald A, Vizeacoumar FJ. Therapeutic relevance of the protein phosphatase 2A in cancer. *Oncotarget*. 2016 Aug; 7 (38) 61544-61561

Dalal Kush, Munuganti Ravi, Morin H  l  ne, Lallous Nada, Rennie Paul S, Cherkasov Artem. Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor. *Methods Mol Biol*. 2016; 1443 31-54

Davies AH, Zoubeidi A. The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells. *Stem Cells International*. 2016 4829602

Deblois Genevi  ve, Smith Harvey W, Tam Ingrid S, Gravel Simon-Pierre, Caron Maxime, Savage Paul, Labb   David P, B  gin Louis R, Tremblay Michel L, Park Morag, Bourque Guillaume, St-Pierre Julie, Muller William J, Gigu  re Vincent. ERR   mediates metabolic adaptations driving lapatinib resistance in breast cancer . *Nature Communications*. 2016; 7 12156

Di Meo A, Pasic MD, Yousef GM. Proteomics and peptidomics: moving toward precision medicine in urological malignancies. *Oncotarget*. 2016 Aug; 7 (32) 52460-52474

Dimitrakopoulos L, Prassas I, Diamandis E, Nesvizhskii A, Kislinger T, Jaffe J, Drabovich A. Proteogenomics: Opportunities and Caveats. *Am Assoc Clin Chem*. 2016 Apr; 62 (4) 551-557

Forbrich A, Shao P, Shi W, Zemp RJ. Lifetime-weighted photoacoustic imaging. *Journal of Optics*. 2016 Dec; 18 124001

Gabril M, Girgis H, Scorilas A, Rotondo F, Wala S, Bjarnason GA, Ding Q, Evans A, Tawedrous E, Pasic M, Finelli A, Al-Haddad S, Yousef GM. S100A11 is a potential prognostic marker for clear cell renal cell carcinoma. *Clinical & Experimental Metastasis*. 2016 Jan; 33 (1) 63-71

Gavin Carson T, Ali Sohrab N, Taily Thomas, Olvera-Posada Daniel, Alenezi Husain, Power Nicholas E, Hou Jinqiang, St Amant Andre H, Luyt Leonard G, Wood Stephen, Wu Charles, Razvi Hassan, Leong Hon S. Novel Methods of Determining Urinary Calculi Composition: Petrographic Thin Sectioning of Calculi and Nanoscale Flow Cytometry Urinalysis. *Sci Rep*. 2016 Jan; 6 19328

Georgescu I, Gooding RJ, Doiron RC, Day A, Selvarajah S, Davidson C, Berman DM, Park PC. Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes. *Cancer and Metabolism*. 2016 May; 4

Geraghty BJ, Lau JY, Chen AP, Cunningham CH.. Accelerated 3D echo-planar imaging with compressed sensing for time-resolved hyperpolarized <sup>13</sup>C studies. *Magnetic Resonance In Medicine*. 2016 Jan; 77

(2) 538-546

Ghiam AF, Taeb S, Huang XY, Huang V, Ray J, Scarcello S, Hoey C, Jahangiri S, Fokas E, Loblaw A, Bristow RG, Vesprini D, Boutros P, Liu SK. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. *Oncotarget*. 2016 Jan; 8 (3) 4668-4689

Gibson E, Bauman GS, Romagnoli C, Cool DW, Bastian-Jordan M, Kassam Z, Gaed M, Moussa M, Gomez JA, Pautler SE, Chin JL, Crukley C, Haider MA, Fenster A, Ward AD. Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion. *International Journal of Radiation Oncology Biology Physics*. 2016 Sep; 96 (1) 188-196

Gibson S, Mihara K, Ei-Daly M, Saifedine M, Hollenberg MD, Hyndman ME. Proteinases, Proteinase-Activated Receptors (PARs) and Transient Receptor Potential (TRP) Ion Channels: Driving Tumorigenesis in the Bladder Cancer Microenvironment. *FASEB Journal*. 2016 Apr; 30 714.2

Gordon JA, Midha A, Szeitz A, Ghaffari M, Adomat HH, Guo Y, Klassen TL, Guns ES, Wasan KM, Cox ME. Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts. *Prostate Cancer and Prostatic Diseases*. 2016 Mar; 19 (1) 21-27

Guo HY, Ahmed M, Hua JJ, Soares F, He HH. Crucial role of noncoding RNA in driving prostate cancer development and progression. *Epigenomics*. 2016 Jan; 9 (1) 1-3

Guo HY, Ahmed M, Zhang F, Yao CQ, Li SD, Liang Y, Hua JJ, Soares F, Sun YF, Langstein J, Li YC, Poon C, Bailey SD, Desai K, Fei T, Li QY, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG, Lupien M, Feng FY, Boutros PC, Freedman ML, Walsh MJ, He HSHS. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. *Nature Genetics*. 2016 Oct; 48 (10) 1142-1150

Haider S, Waggott D, Lalonde E, Fung C, Liu FF, Boutros PC. A bedr way of genomic interval processing. *Source Code for Biology and Medicine*. 2016 Dec; 11 14

Hegemann M, Stenzl A, Bedke J, Chi KN, Black PC, Todenhofer T. Liquid biopsy: ready to guide therapy in advanced prostate cancer?. *BJU Int*. 2016 Dec; 118 (6) 855-863

Hou JQ, Charron CL, Fowkes MM, Luyt LG. Bridging computational modeling with amino acid replacements to investigate GHS-R1a-peptidomimetic recognition. *European Journal of Medicinal Chemistry*. 2016 Nov; 123 822-833

Huang BFF, Boutros PC. The parameter sensitivity of random forests. *BMC Bioinformatics*. 2016 Sep; 17 331

Huang KC, Begin LR, Palanisamy N, Donnelly B, Bismar TA. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker

development. *Urologic Oncology - Seminars and Original Investigations*. 2016 May; 34 (5)

Huynh E, Rajora MA, Zheng G. Multimodal micro, nano, and size conversion ultrasound agents for imaging and therapy. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2016 Nov-Dec; 8 (6) 796-813

Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F. Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. *Scientific Reports*. 2016 Sep; 6 33968

Jin CS, Overchuk M, Cui LY, Wilson BC, Bristow RG, Chen J, Zheng G. Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy. *Prostate*. 2016 Sep; 76 (13) 1169-1181

Karakosta TD, Soosaipillai A, Diamandis EP, Batruch I, Drabovich AP. Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays. *Molecular & Cellular Proteomics*. 2016 Sep; 15 (9) 2863-2876

Keca JM, Chen J, Overchuk M, Muhanna N, MacLaughlin CM, Jin CS, Foltz WD, Irish JC, Zheng G. Nanotexaphyrin: One-Pot Synthesis of a Manganese Texaphyrin-Phospholipid Nanoparticle for Magnetic Resonance Imaging. *Angewandte Chemie*. 2016 May; 55 (21) 6187-6191

Kenmogne LC, Maltais R, Poirier D. Synthesis of a dansyl-labeled inhibitor of 17 beta-hydroxysteroid dehydrogenase type 3 for optical imaging. *Bioorganic and Medicinal Chemistry Letters*. 2016 May; 26 (9) 2179-2183

Komisarenko Maria, Timilshina Narhari, Richard Patrick O, Alibhai Shabbir M H, Hamilton Robert, Kulkarni Girish, Zlotta Alexandre, Fleshner Neil, Finelli Antonio. Stricter Active Surveillance Criteria for Prostate Cancer

do Not Result in Significantly Better Outcomes:

A Comparison of Contemporary Protocols

cancer: A population-based analysis. *Journal of Urology*. 2016 Dec; 196 1645-1650

Kwiatkowska A, Couture F, Levesque C, Ly K, Beauchemin S, Desjardins R, Neugebauer W, Dory YL, Day R. Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors. *ChemMedChem*. 2016 Feb; 11 (3) 289-301

KY, Jeon J, Mejia S, Yao CQ, Ignatchenko V, Nyalwidhe JO, Gramolini AO, Lance RS, Troyer DA, Drake RR, Boutros PC, Semmes OJ, Kislinger T. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. *Nature Communications*. 2016 Jun; 7 11906

KY, Williams KC, Gavin CT, Jardine E, Chambers AF, Leong HS. Quantification of cancer cell extravasation in vivo. *Nature Protocols*. 2016 May; 11 (5) 937-948

Labbe DP, Uetani N, Vinette V, Lessard L, Aubry I, Migon E, Sirois J, Haigh JJ, Begin LR, Trotman LC, Paquet M, Tremblay ML. PTP1B deficiency enables the ability of a high fat diet to drive the invasive

character of PTEN-deficient prostate cancers. *Cancer Research*. 2016 Jun; 76 (11) 3130-3135

Labrecque MP, Takhar MK, Nason R, Santacruz S, Tam KJ, Massah S, Haegert A, Bell RH, Altamirano-Dimas M, Collins CC, Lee FJS, Prefontaine GG, Cox ME, Beischlag TV. The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells. *Oncotarget*. 2016 Aug; 7 (17) 24284-24302

Lallous N, Leblanc E, Munuganti RSN, Hassona MDH, Al Nakouzi N, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns EST, Rennie PS, Cherkasov A. Targeting Binding Function-3 of the Androgen Receptor Blocks its Co-Chaperone Interactions, Nuclear Translocation, and Activation. *Molecular Cancer Therapeutics*. 2016 Dec; 15 (12) 2936-2945

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. *Genome Biology*. 2016 Jan; 17 10

Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Tetu B, Lindberg J, Egevad L, Gronberg H, Ross-Adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.. *Eur Urol*. 2016 July; 72 (1) 22-31

Lam F, Lalansingh CM, Babaran HE, Wang ZY, Prokopec SD, Fox NS, Boutros PC. VennDiagramWeb: a web application for the generation of highly customizable Venn and Euler diagrams. *BMC Bioinformatics*. 2016 Oct; 17 401

Lambert SD, Duncan LR, Kapellas S, Bruson AM, Myrand M, Santa Mina D, Culos-Reed N, Lambrou A.. A Descriptive Systematic Review of Physical Activity Interventions for Caregivers: Effects on Caregivers' and Care Recipients' Psychosocial Outcomes, Physical Activity Levels, and Physical Health. *Annals of Behavioral Medicine*. 2016 Dec; 50 (6) 907-919

Lan M, Li HL, Bao L, Li MP, Lye S, Dong XS. In Vivo Evidence of the Androgen Receptor in Association With Myometrial Cell Proliferation and Apoptosis. *Reproductive Sciences*. 2016 Feb; 23 (2) 264-271

LeGay CM, Gorobets E, Iftinca M, Ramachandran R, Altier C, Derksen DJ. Natural-Product-Derived Transient Receptor Potential Melastatin 8 (TRPM8) Channel Modulators. *Organic Letters*. 2016 Jun; 18 (11) 2746-2749

Li HL, Yu Y, Shi Y, Fazli L, Slater D, Lye S, Dong XS. HoxA13 Stimulates Myometrial Cells to Secrete IL-1 beta and Enhance the Expression of Contraction-Associated Proteins. *Endocrinology*. 2016 May; 157 (5) 2129-2139

Locke JA, Black PC. Next generation biomarkers in prostate cancer. *Front Biosci (Landmark Ed)*. 2016

Jan; 21 328-342

Lowes LE, Goodale D, Xia Y, Postenka C, Piaseczny MM, Paczkowski F, Allan AL. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer. *Oncotarget*. 2016 Nov; 7 (46) 76125-76139

Lu Y-J, Deng Q, Hou J-Q, Hu D-P, Wang Z-Y, Zhang K, Luyt L, Wong W-L, Chow C-F. Molecular engineering of thiazole orange dye: Change of fluorescent signaling from universal to specific upon binding with nucleic acids in bioassay. *ACS Chemical Biology*. 2016 Apr; 11 (4) 1019-1029

Ma JF, Sanchez BJ, Hall DT, Tremblay AMK, Di Marco S, Gallouzi IE. Stat3 Promotes IFN $\gamma$  and TNF $\alpha$  – induced muscle wasting in an NF- $\kappa$ B-dependent and IL-6 independent manner.. *Cancer Research*. 2016 May; 9 (5) 622-637

Macdonald JM, Boutros PC. Log::ProgramInfo: A Perl module to collect and log data for bioinformatics pipelines. *Source Code Biol Med*. 2016; 11 9

Margaillan G, Levesque E, Guillemette C. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. *Journal of Steroid Biochemistry and Molecular Biology*. 2016 Jan; 155 85-93

Masella AP, Lalansingh CM, Sivasundaram P, Fraser M, Bristow RG, Boutros PC. BAMQL: a query language for extracting reads from BAM files. *BMC Bioinformatics*. 2016 Aug; 17 305

Matin F, Jeet V, Clements JA, Yousef GM, Batra J. MicroRNA Theranostics in Prostate Cancer Precision Medicine. *Clin Chem*. 2016 Oct; 62 (10) 1318-1333

Meng F, Saxena S, Joshi B, Shankar J, Moon K, Foster LJ, Bernatchez PN, Nabi IR. Tyrosine phosphorylated caveolin-1 regulates vinculin tension in focal adhesions through its scaffolding domain.. *Molecular Biology of the Cell*. 2016; 27 P2244

Mihara K, Ramachandran R, Saifeddine M, Hansen KK, Renaux B, Polley D, Gibson S, Vanderboor C, Hollenberg MD. Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling. *Molecular Pharmacology*. 2016 May; 89 (5) 606-614

Milosevich N, Gignac MC, McFarlane J, Simhadri C, Horvath S, Daze KD, Croft CS, Dheri A, Quon TTH, Douglas SF, Wulff JE, Paci I, Hof F. Selective Inhibition of CBX6: A Methyllysine Reader Protein in the Polycomb Family. *ACS Medicinal Chemistry Letters*. 2016 Feb; 7 (2) 139-144

Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. *Nature Reviews Cancer*. 2016 Nov; 16 (11) 718-731

Murray D, Mirzayans R, Parliament M. New insights into patient radiosensitivity in relation to the biology of the ATM protein. *Translational Cancer Research*. 2016 Oct; 5 S809-S814

Neveu B, Jain P, Tetu B, Wu L, Fradet Y, Pouliot F. A PCA3 gene-based transcriptional amplification

system targeting primary prostate cancer. *Oncotarget*. 2016 Jan; 7 (2) 1300-1310

Ng KK, Takada M, Harmatys K, Chen J, Zheng G. Chlorosome-Inspired Synthesis of Templated Metallochlorin-Lipid Nanoassemblies for Biomedical Applications. *ACS Nano*. 2016 Apr; 10 (4) 4092-4101

Ng KK, Weersink RA, Lim L, Wilson BC, Zheng G. Controlling Spatial Heat and Light Distribution by Using Photothermal Enhancing Auto-Regulated Liposomes (PEARLs). *Angewandte Chemie*. 2016 Aug; 55 (34) 10003-10007

Nofech-Mozes R, Khella HWZ, Scorilas A, Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans A, Yousef GM. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. *Cancer Medicine*. 2016 Apr; 5 (4) 656-664

Park ES, Jin C, Guo Q, Ang RR, Duffy SP, Matthews K, Azad A, Abdi H, Todenhofer T, Bazov J, Chi KN, Black PC, Ma HS. Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets. *Small*. 2016 Apr; 12 (14) 1909-1919

Patel PG, Selvarajah S, Boursalie S, How NE, Ejdelman J, Guerard KP, Bartlett JM, Lapointe J, Park PC, Okello JBA, Berman DM. Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction. *Journal of Visualized Experiments*. 2016 Aug; 114 e54299

Peant B, Gilbert S, Le Page C, Poisson A, L'Ecuyer E, Boudhraa Z, Bienz MN, Delvoe N, Saad F, Mes-Masson AM. I kappa B-Kinase-epsilon (IKK epsilon) over-expression promotes the growth of prostate cancer through the C/EBP-beta dependent activation of IL-6 gene expression. *Oncotarget*. 2016 Feb; 8 (9) 14487-14501

Prud'homme GJ, Glinka Y, Lichner Z, Yousef GM. Neuropilin-1 is a receptor for extracellular miRNA and AGO2/miRNA complexes and mediates the internalization of miRNAs that modulate cell function. *Oncotarget*. 2016 Oct; 7 (42) 68057-68071

Raeesi V, Chan WCW. Improving nanoparticle diffusion through tumor collagen matrix by photothermal gold nanorods. *Nanoscale*. 2016 8 (25) 12524-12530

Raeesi Vahid, Chou Leo Y T, Chan Warren C W. Tuning the drug loading and release of DNA-assembled gold nanorod superstructures . *Advanced Materials*. 2016 Aug

Rajora MA, Zheng G. Targeting SR- BI for Cancer Diagnostics, Imaging and Therapy. *Frontiers in Pharmacology*. 2016 Sep; 7 326

Ramachandran R, Altier C, Oikonomopoulou K, Hollenberg MD. Proteinases, Their Extracellular Targets, and Inflammatory Signaling. *Pharmacological Reviews*. 2016 Oct; 68 (4) 1110-1142

Read Jolene, Ingram Alistair, Al Saleh Hassan A, Platko Khrystyna, Gabriel Kathleen, Kapoor Anil, Pinthus Jehonathan, Majeed Fadwa, Qureshi Talha, Al-Nedawi Khalid. Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles.



European Journal of Cancer. 2016 Jan; 70 62-74

Richard Patrick O, Alibhai Shabbir M H, Panzarella Tony, Klotz Laurence, Komisarenko Maria, Fleshner Neil E, Urbach David, Finelli Antonio. The uptake of active surveillance for the management of prostate cancer: A population-based analysis. Canadian Urological Association Journal. 2016 10 (43017) 333-338

Rot I, Wassersug RJ, Walker LM. What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product. Transl Androl Urol.. 2016 Apr; 5 (2) 235

Samudio Ismael, Rezvani Katayoun, Shaim Hila, Hofs Elyse, Ngom Mor, Bu Luke, Liu Guoyu, Lee Jason T C, Imren Suzan, Lam Vivian, Poon Grace F T, Ghaedi Maryam, Takei Fumio, Humphries Keith, Jia William, Krystal Gerald. UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells. Blood. 2016 May; 127 2575-2586

Shahedi M, Cool DW, Romagnoli C, Bauman GS, Bastian-Jordan M, Rodrigues G, Ahmad B, Lock M, Fenster A, Ward AD. Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study. Journal of Medical Imaging. 2016 Oct; 3 46002

Shi W, Paproski RJ, Shao P, Forbrich A, Lewis JD, Zemp RJ. Multimodality Raman and photoacoustic imaging of surface-enhanced-Raman-scattering-targeted tumor cells. Journal of Biomedical Optics. 2016 Feb; 21 20503

Shi W, Pawlick R, Bruni A, Rafiei Y, Pepper AR, Gala-Lopez B, Choi M, Malcolm A, Zemp RJ, Shapiro AMJ. Photoacoustic imaging of angiogenesis in a subcutaneous islet transplant site in a murine model. Journal of Biomedical Optics. 2016 Jun; 21 66003

Sidiropoulos KG, Ding Q, Pampalakis G, White NMA, Boulos P, Sotiropoulou G, Yousef GM. KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. Molecular Oncology. 2016 Aug; 10 (7) 993-1007

Simhadri C, Gignac MC, Anderson CJ, Milosevich N, Dheri A, Prashar N, Flemmer RT, Dev A, Henderson TG, Douglas SF, Wulff JE, Hof F. Structure-Activity Relationships of Cbx7 Inhibitors, Including Selectivity Studies against Other Cbx Proteins. ACS Omega. 2016 Oct; 1 (4) 541-551

Singhal Sandeep K, Usmani Nawaid, Michiels Stefan, Metzger-Filho Otto, Saini Kamal S, Kovalchuk Olga, Parliament Matthew. Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. Oncotarget. 2016 Jan; 7 3002-3017

Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang YZ, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget. 2016 Feb; 8 (6) 9617-9633

Todenhofer T, Park ES, Duffy S, Deng XY, Jin C, Abdi H, Ma HS, Black PC. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer. *Urologic Oncology*. 2016 Nov; 34 (11)

Toren P, KS, Johnson F, Zoubeidi A. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. *PLoS One*. 2016 Apr; 11 (4) e0152861

Tourancheau A, Margailan G, Rouleau M, Gilbert I, Villeneuve L, Levesque E, Droit A, Guillemette C. Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. *Pharmacogenomics Journal*. 2016 Feb; 16 (1) 60-70

Tsukumo Y, Alain T, Fonseca BD, Nadon R, Sonenberg N. Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3. *Nature Communications*. 2016 Jun; 7 11776

Vahid S, Thaper D, Gibson KF, Bishop JL, Zoubeidi A. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer. *Scientific Reports*. 2016 Aug; 6 31842

Valic MS, Zheng G. Rethinking translational nanomedicine: insights from the 'bottom-up' design of the Porphyosome for guiding the clinical development of imageable nanomaterials. *Current Opinion in Chemical Biology*. 2016 Aug; 33 126-134

Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies. *Molecular Cancer Research*. 2016 Oct; 14 (10) 898-908

Walker LM, King N, Kwasny Z, Robinson JW. Intimacy after prostate cancer: A brief couples' workshop is associated with improvements in relationship satisfaction.. *Psychooncology*. 2016 Sep; 26 (9) 1336-1346

Wang TT, Abou-Ouf H, Hegazy SA, Alshalalfa M, Stoletov K, Lewis J, Donnelly B, Bismar TA. Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients. *Journal of Molecular Medicine*. 2016 Dec; 94 (12) 1411-1422

Wang YZ, Wang JX, Xue H, Lin D, Dong X, Gout PW, Gao X, Pang J. Subrenal capsule grafting technology in human cancer modeling and translational cancer research. *Differentiation*. 2016 Apr-Jun; 91 15-19

White-Al Habeeb NMA, Garcia J, Fleshner N, Bapat B. Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells. *The Prostate*. 2016 Dec; 76 (16) 1507-1518

Wyatt A, Azad A, Volik S, Annala M, Beja K, McConeghy B, Haegert A, Warner E, Mo F, Brahmabhatt S, Shukin R, Le Bihan S, Gleave M, Nykter M, Collins C, Chi K. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. *JAMA Oncology*. 2016 Dec; 2 (12) 1598-1606

Wyatt AW, Annala M, Beja K, Parimi S, Vandekerkhove G, Warner E, Zulfiqar M, Finch D, Oja C,

Vergidis J, Nykter M, Gleave ME, Chi K. Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy. *Annals of Oncology*. 2016 Oct; 27 59P

Yamamoto T, Musunuru B, Vesprini D, Zhang LY, Ghanem G, Loblaw A, Klotz L. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance. *Journal of Virology*. 2016 May; 195 (5) 1409-1414

Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. *Journal of Controlled Disease*. 2016 Oct; 240 332-348

Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, Zlotta AR, Loblaw A, Fleshner NE, Klotz L, Vesprini D, Bapat B. Urinary DNA methylation biomarkers for non-invasive prediction of aggressive disease in patients with prostate cancer on active surveillance. *Journal of Urology*. 2016 Feb; 197 (2) 335-341

Zhou S, Treloar AE, Lupien M. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. *Cancer Discovery*. 2016 Nov; 6 (11) 1215-1229